Is UnitedHealth Group, Inc. overvalued or undervalued?

As of 9 September 2025, the valuation grade for UnitedHealth Group, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued, with a P/E ratio of 12, which is lower than its peers such as The Cigna Group at 15.76 and Elevance Health, Inc. at 12.97. Additionally, the EV to EBITDA ratio stands at 77.36, significantly higher than the industry average, and the PEG ratio is notably low at 0.28, suggesting that growth expectations may not justify the current price.
In terms of performance, UnitedHealth has underperformed relative to the S&P 500, with a year-to-date return of -33.81% compared to the index's 12.22%. Over the past year, the stock has declined by 42.34%, while the S&P 500 has gained 17.14%. This stark contrast in returns further reinforces the notion that UnitedHealth Group, Inc. is currently overvalued.